Topics

Phagocytosis Checkpoint-Mediated Tumor Immune Escape

Cancer Immunotherapy Tumor Microenvironment Intercellular Communication & Diseases

Phagocytosis checkpoint-mediated tumor immune escape describes how cancer cells block macrophage and dendritic-cell clearance by expressing antiphagocytic “don’t eat me” signals. Innate immune checkpoints interfere with malignant-cell detection and phagocytic clearance, and the CD47-SIRPα axis is the best-established pathway linking tumor immune escape to macrophage suppression. This mechanism expands cancer immunotherapy beyond T-cell checkpoints by targeting innate immune surveillance and antigen presentation[1][2].

Mechanistically, CD47 on tumor cells binds SIRPα on macrophages, transmits an inhibitory signal, and suppresses phagocytosis. CD47 expression is observed in multiple cancers and can be induced by NF-κB, MYC, and HIF. Blocking CD47-SIRPα enhances tumor-cell clearance by macrophages and dendritic cells, promotes antigen cross-presentation, supports T-cell priming, and connects innate immune activation to adaptive antitumor immunity[2][3].

Disease applications include hematologic malignancies, small-cell lung cancer, non-small-cell lung cancer, glioblastoma, anaplastic thyroid carcinoma, multiple myeloma, and solid-tumor combination therapy. Anti-CD47 treatment promoted macrophage phagocytosis and suppressed tumor growth in anaplastic thyroid carcinoma models, while CD47-blocking immunotherapies stimulated macrophage-mediated destruction of small-cell lung cancer. Nanoparticle-mediated CD47-SIRPα blockade combined with doxorubicin increased calreticulin exposure as an “eat me” signal, enhanced macrophage phagocytosis, improved antigen cross-presentation, and increased CD8+ T-cell infiltration[4][5][6].

Key gaps include anemia and hematotoxicity, limited single-agent efficacy in some solid tumors, insufficient “eat me” signaling, myeloid-cell heterogeneity, tumor-antigen specificity, and resistance through alternative checkpoints such as CD24-Siglec10, TREM2, and glycan-binding pathways. Future strategies should prioritize selective SIRPα blockade, bispecific antibodies, CAR-macrophages, tumor-opsonizing antibodies, nanomedicine co-delivery, and combinations with PD-1/PD-L1 blockade to coordinate macrophage phagocytosis with durable T-cell immunity[1][6][7][8].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-100941 CCCP
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
PINK1/Parkin   Oxidative Phosphorylation   STING   IFNAR   Mitochondrial Metabolism   Bacterial   Apoptosis  
Non-Small Cell Lung Cancer   Mycobacterium Tuberculosis Infection   Parkinson's Disease  
192
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L014 NF-κB Signaling Compound Library
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. MCE owns a unique collection of 1,801 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Signaling Pathway Targeting Libraries

85
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L156 Autoimmune Disease Compound Library
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Disease Focused Libraries

83
HY-L161 Cytokine Inhibitors Library
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases. MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Signaling Pathway Targeting Libraries

83
HY-L174 Macrophage Related Compound Library
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L237 Pattern Recognition Receptors Library
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions. MCE has cataloged 338 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-10964 Vadimezan
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
STING   IFNAR   Influenza Virus  
Prostate Cancer   Viral Infection   Autoimmune Disease   Non-Small Cell Lung Cancer  
80
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-123606 GSK484
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8+ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.
Protein Arginine Deiminase   MHC  
Digestive System Disease   Colitis   Sickle Cell Disease   Cardiomyopathy   Rheumatoid Arthritis  
57
HY-100564A 2',3'-cGAMP sodium
2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-100564 2',3'-cGAMP
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-117287 Deucravacitinib
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
JAK   STAT   Interleukin Related   IFNAR  
Systemic Lupus Erythematosus   Psoriasis   Inflammatory Bowel Disease  
36
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P1489A OVA Peptide(257-264) TFA
OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P1489 OVA Peptide(257-264)
OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-134581 Enpatoran
Enpatoran (M5049) is an orally active and selective TLR7/8 antagonist. Enpatoran inhibits the activation of the downstream type I interferon pathway. Enpatoran is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis.
Toll-like Receptor (TLR)   IFNAR  
Systemic Lupus Erythematosus   Psoriasis  
18
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-147124 RIG012
RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
IFNAR  
Cancer   Infection  
6
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
Interleukin Related   IFNAR  
Allergic Asthma   Allergic Rhinitis  
6
HY-P99029 Magrolimab
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer.

Species: Human

CD47  
HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer  
5
HY-P99168 Anifrolumab
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.

Species: Human

IFNAR  
Systemic Lupus Erythematosus   Rheumatoid Arthritis  
5
HY-P3970 KRFK
KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach.
TGF-β Receptor  
Inflammation or Immune System Disease  
4
HY-123941 FKBP12 PROTAC dTAG-7
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRASG12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research.
PROTACs   FKBP   Epigenetic Reader Domain   HDAC   Histone Methyltransferase   c-Myc   Polo-like Kinase (PLK)   Ras   MHC  
Leukemia/Lymphoma/Myeloma  
4
HY-P3970A KRFK TFA
KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach.
TGF-β Receptor  
Inflammation or Immune System Disease  
4
HY-B2123 Lactose
Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
Environmental Pollutants   ERK   Interleukin Related   Endogenous Metabolite   NF-κB  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity  
4
HY-N1939 Icariside I
Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape.
Apoptosis   Reactive Oxygen Species (ROS)   NOD-like Receptor (NLR)   STAT   CDK   Bcl-2 Family   Aryl Hydrocarbon Receptor   JAK   Caspase   IFNAR   PD-1/PD-L1  
Metabolic or Endocrine Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Autoimmune Disease   Digestive System Inflammation  
3
HY-32350 Ercalcitriol
Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
VD/VDR   Drug Metabolite   Endogenous Metabolite  
Metabolic or Endocrine Disease  
3
HY-D0970 Diphenyl Blue
Diphenyl Blue (Trypan Blue) is a cell active dye, the most commonly used dye for the identification of dead cells, of en used to test cell membrane integrity and cell viability. Diphenyl Blue staining is one of the methods for tissue and cell culture. When cells are deactivated or have incomplete cell membranes, Diphenyl Blue can stain them Blue. Normal living cells with intact cell membranes reject Diphenyl blue and do not stain them blue. However, macrophages are capable of phagocytosis of Diphenyl Blue, so it can be used as a living stain for macrophages.
Fluorescent Dye  
3
HY-P990131 Anti-Mouse CD47/IAP Antibody (MIAP301)
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis.

Species: Mouse

CD47  
Melanoma   Klebsiella Pneumoniae Infection   Sepsis  
2
HY-109520 Glatiramer acetate
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
MHC  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
2
HY-N6727 Gliotoxin
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis. Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells. Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells.

Source: Aspergillus fumigatus

Apoptosis   PKA   NF-κB   Bacterial   Fungal   Antibiotic  
Cancer   Infection   Inflammation or Immune System Disease  
2
HY-119109 Laminaran
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Source: Eisenia Bicyclis

Environmental Pollutants   C-type Lectin-like Receptors (CTLRs)   Endogenous Metabolite  
Colorectal Cancer  
2
HY-125859 Peroxidase, Horseradish
Peroxidase, Horseradish actively involves in oxidizing reactive oxygen species, innate immunity, hormone biosynthesis and pathogenesis of several diseases.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-P84229 Calreticulin Antibody (YA3926)
Calreticulin Antibody (YA3926) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Calreticulin.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

2
HY-141567 Pseudouridine 5'-triphosphate
Pseudouridine 5'-triphosphate (Pseudo-UTP) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate can be used for the research of vaccinia virus infection.
DNA/RNA Synthesis  
Viral Infection  
1
HY-N6689 Destruxin A
Destruxin A is a fungal cyclopeptide with insecticidal and antiviral activities. Destruxin A has a certain inhibitory effect on leukemia cells in vitro. Destruxin A can also specifically inhibit the innate immune response of Drosophila melanogaster, making the flies more susceptible to bacterial infections.

Source: Metarhizium anisopliae

Insecticide   Bacterial  
Cancer   Infection   Inflammation or Immune System Disease  
1
HY-P99700 Letaplimab
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis.

Species: Human

Others  
Lung Adenocarcinoma  
1
HY-P99706 Ligufalimab
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.

Species: Human

CD47   Interleukin Related  
Cancer  
1
HY-N5084 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
TRP Channel   HDAC   p38 MAPK   JNK   ERK   NF-κB   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Bladder Cancer   Pain  
1
HY-P99777 Ontorpacept
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
CD47  
Cancer  
1
HY-D1056H Lipopolysaccharides, from S. marcescens
Lipopolysaccharides, from S. marcescens (Serratia marcescens) are lipopolysaccharide endotoxins and TLR-4 activators derived from Serratia marcescens, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. marcescens exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from S. marcescens induce NF-κB activation in mouse cells via Toll-like receptor (TLR4)/MD-2. The lipopolysaccharides of S. marcescens can induce apoptosis in host immune cells, thereby suppressing the host's innate immunity.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-141567A Pseudouridine 5'-triphosphate trisodium solution (100 mM)
Pseudouridine 5'-triphosphate (Pseudo-UTP) trisodium solution (100 mM) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate trisodium solution (100 mM) enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate trisodium solution (100 mM) can be used for the research of vaccinia virus infection.
DNA/RNA Synthesis  
Viral Infection  
1
HY-P99533 Urabrelimab
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

Species: Human

CD47   Interleukin Related  
Cancer  
1
HY-125527 Resolvin D1
Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages.
Endogenous Metabolite  
Inflammation or Immune System Disease  
1
HY-126855 Cholic acid 7-sulfate
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
G protein-coupled Bile Acid Receptor 1   MHC  
Glucose Metabolism   Obesity  
1
HY-P99044 Sabatolimab
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.

Species: Human

Tim3  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
1
HY-W041892 Dimethyl itaconate
Dimethyl itaconate induces innate immune memory (trained immunity), and exhibits immunomodulatory property. Dimethyl itaconate inhibits the activation of microglia, reduces the neuroinflammation and synaptic structural damage. Dimethyl itaconate regulates the composition of intestinal flora.
Reactive Oxygen Species (ROS)  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P72917 CD47 Protein, Human (HEK293)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (HEK293) is the recombinant human-derived CD47 protein, expressed by HEK293 , with tag free.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

1
HY-P72112 Calreticulin/CALR Protein, Mouse (GST)
The calreticulin/CALR protein acts as a calcium-binding partner and promotes endoplasmic reticulum folding, assembly, and quality control. It interacts with monoglucosylated glycoproteins and mediates nuclear export of the NR3C1 DNA-binding domain. Calreticulin/CALR Protein, Mouse (GST) is the recombinant mouse-derived Calreticulin/CALR protein, expressed by E. coli , with N-GST labeled tag.

Species: Mouse; Source: E. coli

1
HY-P700826 SIRP alpha V8/CD172a Protein, Human (Biotinylated, S44L, S50T, I52T, H54R, V57A, HEK293, His-Avi)
SIRP alpha V8/CD172a Protein, Human (Biotinylated, S44L, S50T, I52T, H54R, V57A, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V8/CD172a protein, expressed by HEK293, with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

1
HY-P80043 Calreticulin Antibody (YA571)
Calreticulin Antibody is a non-conjugated and Rabbit origined IgG monoclonal antibody, targeting to Calreticulin. It can be used as a loading control antibody.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Loading Controls Antibodies Primary Antibodies

1
HY-P3968 Thrombospondin-1 (1016-1021) (human, bovine, mouse)
Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.
CD47  
/
HY-P992338 CT-1119
CT-1119 is an autologous human anti-Mesothelin chimeric antigen receptor macrophage (CAR-M). CT-1119 mediates CAR-dependent, antigen-dependent functional activities. CT-1119 acts as a phagocytosis inducer, tumor cell killer, pro-inflammatory cytokine inducer, and M1 macrophage polarizer. CT-1119 exhibits stronger resistance to M2 repolarization and reduces tumor burden in a mouse lung cancer xenograft model. CT-1119 can be used for the research of mesothelin-expressing solid tumors.

Species: Human

Mesothelin   Constitutive Androstane Receptor  
Inflammation or Immune System Disease   Lung Cancer  
/
HY-P991039 Zamubafusp alfa
Zamubafusp alfa (AT-02) is an immunoglobulin-peptide fusion protein consisting of a humanized IgG1 and the pan-amyloid reactive peptide p5R. Zamubafusp alfa binds to two ubiquitous components of all amyloids, namely amyloid fibrils and highly sulfated heparan sulfate glycans. Zamubafusp alfa enhances macrophage phagocytosis for amyloid clearance and can be used in research related to systemic amyloidosis.
Amyloid-β  
Inflammation or Immune System Disease  
/
HY-124410S Mitoquinol-d15
Mitoquinol-d15 is deuterium labeled Mitoquinol (HY-124410). Mitoquinol is an orally active mitochondria-targeted antioxidant. Mitoquinol can regulate mitochondrial respiration and oxidation. Mitoquinol inhibits ROS production, and improves phagocytosis and glycolysis in ethanol-exposed macrophages via the HIF-1α-PFKP axis. Additionally, Mitoquinol can partially alleviate heat stress-induced decreases in growth performance, inflammatory responses, and metabolic disorders in pigs.
Isotope-Labeled Compounds   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P991927 ZL-1201
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer.

Species: Human

CD47  
Breast Cancer   Gastric Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P11205 Cys-PKHB1
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-169089A RP-182-PEG3-K(palmitic acid)-NH2 TFA
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts.
Drug Derivative  
Cancer  
/
HY-P991305 AGEN-1571
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P2291 Beta-defensin 103 isoform X1, pig
Beta-defensin 103 isoform X1, pig is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
Bacterial  
Inflammation or Immune System Disease  
/
HY-P11886 GNYTCEVTELTREGETIIELK-N3
GNYTCEVTELTREGETIIELK-N3 (GNYTCEVTELTREGETIIELK-Azide) is a conjugate of an azide (-N3) group and a CD47 functional peptide (GNYTCEVTELTREGETIIELK). Modifying the surface of LNPs with GNYTCEVTELTREGETIIELK significantly reduces the recognition and clearance of LNPs by the mononuclear phagocytic system (MPS) and reduces their accumulation in non-target tissues such as the liver and spleen. The azide group in GNYTCEVTELTREGETIIELK-N3 can undergo click chemistry reactions for applications such as constructing targeted drug delivery systems and nanoparticle modification.
Biochemical Assay Reagents  
/
HY-P3151A Gliadin p31-43 TFA
Gliadin p31-43 TFA is an undigested gliadin peptide. Gliadin p31-43 TFA induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 TFA can be used for celiac disease research.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P1813 PSA1 (141-150)
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
Prostaglandin Receptor  
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P992051 Anti-CD103 Antibody (hCD103.01A)
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Integrin  
Cancer   Inflammation or Immune System Disease  
/
HY-169089 RP-182-PEG3-K(palmitic acid)-NH2
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts.
Drug Derivative  
Cancer  
/
HY-P10947 MACTIDE-V
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206+ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models.
Epigenetic Reader Domain   YAP  
/
HY-P991367 ES004
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research.

Species: Human

CD47  
Cancer  
/
HY-P10707A Tpp-CAQK TFA
Tpp-CAQK TAF can bind to mitochondria, enabling the construction of an engineered mitochondrial compound, Mito-Tpp-CAQK TFA, with excellent bioactivity. Mito-Tpp-CAQK TFA can be internalized by macrophages, thereby enhancing the phagocytosis of myelin debris, alleviating mitochondrial dysfunction, and reducing proinflammatory profiles, ultimately facilitating tissue repair and functional recovery in mice after spinal cord injury.
Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-P4130 MPS-Gαi2
MPS-Gαi2 is a membrane-permeable inhibitory peptide corresponding to the C-terminal sequence of Gαi2 involved in receptor interaction. MPS-Gαi2 blocks Hep I-induced binding of Gαi2 to LRP, thereby inhibiting pertussis toxin-sensitive Gαi2 signaling and focal adhesion disassembly mediated by thrombospondin/Hep I-calreticulin-LRP. MPS-Gαi2 can be used in studies on G protein signaling and cell adhesion regulation.
Others  
Bacterial Infection  
/
HY-P991634 IBI-325
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.

Species: Human

CD73   TNF Receptor   Interleukin Related   IFNAR  
Cancer   Inflammation or Immune System Disease  
/
HY-P991954 GT103
GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer.

Species: Human

Complement System   Syk  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-20457G TL8-506 (GMP)
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
Toll-like Receptor (TLR)   Bacterial   Interleukin Related  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P10371 PKHB1
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8+ T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia.
Reactive Oxygen Species (ROS)   Thrombopoietin Receptor   Mitochondrial Metabolism   HSP   HSV   CD47  
Inflammation or Immune System Disease   Breast Cancer   Acute Lymphoblastic Leukemia   HSV Infection  
/
HY-P992351 ELB021
ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8+ T cell-mediated cytotoxicity. Independent of PD-1 regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection.

Species: Human

Others  
Leukemia/Lymphoma/Myeloma   HIV-1 Infection  
/
HY-P10707 Tpp-CAQK
Tpp-CAQK can bind to mitochondria, enabling the construction of an engineered mitochondrial compound, Mito-Tpp-CAQK, with excellent bioactivity. Mito-Tpp-CAQK can be internalized by macrophages, thereby enhancing the phagocytosis of myelin debris, alleviating mitochondrial dysfunction, and reducing proinflammatory profiles, ultimately facilitating tissue repair and functional recovery in mice after spinal cord injury.
Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-122292 Celastramycin A
Celastramycin A is an antibiotic isolated from Streptomyces MaB-QuH-8, which exhibits antimicrobial activity against series of gram-negative bacteria and mycobacteria, with MICs between 0.05-3.1 μg/ml. Celastramycin A exhibits immunosuppressing efficacy in ex vivo Drosophila through immune deficiency pathway (IC50 of 0.008 μg/ml), inhibits the immunoresponse in human innate immunity through TNF-α signaling, inhibits IL-8 production in HUEVCs with IC50 of 0.06 μg/ml.

Source: Drosophila

Antibiotic   Bacterial  
Infection   Inflammation or Immune System Disease  
/
HY-P2291A Beta-defensin 103 isoform X1, pig TFA
Beta-defensin 103 isoform X1, pig TFA is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
Bacterial  
Inflammation or Immune System Disease  
/
HY-N6714R Alternariol (Standard)
Alternariol (Standard) is the analytical standard of Alternariol. This product is intended for research and analytical applications. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
Reference Standards   Topoisomerase   Androgen Receptor   Estrogen Receptor/ERR   Apoptosis  
Cancer   Infection  
/
HY-P2457 rCRAMP (rat)
rCRAMP (rat) is the rat cathelin-related antimicrobial peptide. rCRAMP (rat) contributes to the antibacterial activity in rat brain peptide/protein extracts. rCRAMP (rat) is a potential key player in the innate immune system of rat CNS.
Bacterial  
Inflammation or Immune System Disease  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-N12905 Celastramycin A (isomer)
Celastramycin A isomer is an isomer of Celastramycin A (HY-122292), an antibiotic against Gram-negative bacteria and Mycobacterium tuberculosis with an MIC of 0.05-3.1 μg/mL. Celastramycin A exerts immunosuppressive effects in Drosophila ex vivo via the immunodeficiency pathway (IC50 of 8 ng/mL), inhibits human innate immune responses via the TNF-α pathway, and inhibits IL-8 production in HUEVC with an IC50 of 60 ng/mL.

Source: Streptomyces strains

Antibiotic   Bacterial  
/
HY-N1939R Icariside I (Standard)
Icariside I (Standard) is the analytical standard of Icariside I (HY-N1939). This product is intended for research and analytical applications. Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape.
Reference Standards   Apoptosis   Reactive Oxygen Species (ROS)   NOD-like Receptor (NLR)   STAT   CDK   Bcl-2 Family   Aryl Hydrocarbon Receptor   JAK   Caspase   IFNAR   PD-1/PD-L1  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P5407 HD5
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
SARS-CoV   Angiotensin-converting Enzyme (ACE)  
Colorectal Cancer   Small Cell Lung Cancer   Epithelial Ovarian Cancer   SARS-CoV-2 Infection   HPV Infection  
/
HY-N16463 QS-S2
QS-S2 is the impurity of QS-21 (HY-101092A). QS-21 is an innate immune system-targeted adjuvant.
Drug Intermediate  
/
HY-111582G BBIQ (GMP)
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of  59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-32350S1 Ercalcitriol-d3
Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
Isotope-Labeled Compounds   VD/VDR   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-W653896 Alternariol-d2
Alternariol-d2 is deuterium labeled Alternariol. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
Isotope-Labeled Compounds   Topoisomerase   Apoptosis   Androgen Receptor   Estrogen Receptor/ERR  
Infection  
/
HY-P2076A Dusquetide TFA
Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
p62   Bacterial  
Infection  
/
HY-144002 RIBI-529
RIBI-529 (RC-529) is a fully synthetic, low-toxicity TLR4 agonist vaccine adjuvant. RIBI-529 upregulates cell surface co-stimulatory molecules, receptors, cytokines and chemokines, and activates the innate immune system. RIBI-529 enhances short-term CD4+ T cell clonal expansion, division, and ex vivo survival under growth factor withdrawal conditions. RIBI-529 enhances humoral and cell-mediated adaptive immune responses, induces non-specific resistance against viral and bacterial pathogens, and skews responses toward a Th1 type, accompanied by Th2 responses.
Toll-like Receptor (TLR)   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P991126 Ciltistotug
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991125 Cenzestotug
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P10813 ZLIRTLHEWY
ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers.
CD47  
Cancer   Inflammation or Immune System Disease  
/
HY-P11108A RP-182 acetate
RP-182 acetate is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 acetate induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 acetate has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 acetate is used in pancreatic cancer and melanoma research.
NF-κB   Apoptosis   TNF Receptor   Caspase  
Cancer   Inflammation or Immune System Disease  
/
HY-P99709 Lodapolimab
Lodapolimab (LY3300054) is a fully human IgG1λ anti-PD-L1 monoclonal antibody, with an EC50 of 0.075 nM against hPD-L1 and an EC50 of 0.085 nM against cynomolgus monkey PD-L1. Lodapolimab induces naive T cell activation, enhances the T cell activation effect of anti-CTLA4 antibodies, promotes anti-tumor alloreactivity, regulates innate immune pathways, and induces characteristics of adaptive immune activation. Lodapolimab can be used in research related to high-grade serous ovarian cancer and other solid tumors.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease   Ovarian Cancer   Triple-Negative Breast Cancer  
/
HY-P991057 STI-6643
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 blocks CD47-SIRPα interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

CD47  
Leukemia/Lymphoma/Myeloma  
/
HY-P10217 PD-1/PD-L1-IN-42
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P991016 Peluntamig
Peluntamig (PT-217) is a bispecific antibody targeting DLL3 and CD47. The antibody arms of Peluntamig specifically bind to DLL3 on small cell lung cancer tumor cells while blocking the CD47-SIRPa interaction, thereby effectively stimulating macrophage phagocytosis and inducing NK cell-mediated cytotoxicity. Peluntamig exhibits significant anti-tumor activity against small cell lung cancer and also has favorable safety profiles. Peluntamig can be used in a variety of tumor-related studies including those on small cell lung cancer and L1210 leukemia.

Species: Human

CD47  
Inflammation or Immune System Disease  
/
HY-P11097 Pep-20
Pep-20 is a CD47 binder with a human Kd of 2.91 µM and a murine Kd of 3.63 µM. Pep-20 blocks the interaction between CD47 and SIRPα, with an IC50 of 24.56 µM for human targets and 12.03 µM for murine targets. Pep-20 also acts as a phagocytosis enhancer and an inducer of anti-tumor immune responses. By blocking the CD47/SIRPα interaction, Pep-20 reduces the tyrosine phosphorylation level of SIRPα, disrupts the inhibitory "don't eat me" signaling pathway, enhances macrophage-mediated phagocytosis of solid tumor cells and hematologic tumor cells, and promotes macrophage mobilization of anti-tumor T-cell responses. Pep-20 can be used in research related to solid tumors, hematologic malignancies, breast cancer, and pancreatic cancer.
CD47  
Breast Cancer   Pancreatic Cancer   Blood Disease  
/
HY-W145481A D-Galacto-D-mannan
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease.
C-type Lectin-like Receptors (CTLRs)   Sirtuin  
Inflammation or Immune System Disease  
/
HY-P2320 IDR-1
IDR-1 is an antimicrobial peptide that is active against Gram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and anti-infective properties, enhances the levels of monocyte chemokines, and attenuates pro-inflammatory cytokine release.
Bacterial  
Inflammation or Immune System Disease  
/
HY-P991401 GSK2862277
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P10862A AH-D peptide TFA
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P11205A Cys-PKHB1 TFA
Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-N9680 Coenzyme Q8
Coenzyme Q8 (Ubiquinone 8) is an isoprenoid quinone that mediates electron transfer within the aerobic respiratory chain and reduces oxidative stress. Coenzyme Q8 maintains bacterial respiratory function and enhances host resistance to bacterial infection. Coenzyme Q8 stimulates macrophage phagocytosis and increases antibody-producing cells. Coenzyme Q8 can be used in infectious disease research.
Endogenous Metabolite   Bacterial  
Infection   Inflammation or Immune System Disease  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-W015600S 2-Acetamidophenol-d3
2-Acetamidophenol-d3 (Orthocetamol-d3) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation.
Isotope-Labeled Compounds   Reactive Oxygen Species (ROS)   Glutathione Peroxidase   Ferroptosis   LDLR  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P990707 Maplirpacept
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47.

Species: Human

CD47  
Inflammation or Immune System Disease  
/
HY-P10862 AH-D peptide
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50
values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P990782 Efzofitimod
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD).

Species: Human

Aminoacyl-tRNA Synthetase  
Inflammation or Immune System Disease  
/
HY-B2123R Lactose (Standard)
Lactose (Standard) is the analytical standard of Lactose. This product is intended for research and analytical applications. Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
Reference Standards   Endogenous Metabolite   Interleukin Related   ERK   NF-κB  
Inflammation or Immune System Disease  
/
HY-P991023 Safimestomig
Safimestomig (6MW3211) is an CD47/PD-L1-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer.

Species: Human

CD47   PD-1/PD-L1  
Cancer  
/
HY-P99928 Efprezimod alfa
Efprezimod alfa (MK 7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome.
Transmembrane Glycoprotein  
Cancer  
/
HY-P99834 Crefmirlimab
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.

Species: Human

Transmembrane Glycoprotein  
Lung Cancer  
/
HY-P11108 RP-182
RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research.
NF-κB   Apoptosis   TNF Receptor   Caspase  
Inflammation or Immune System Disease  
/
HY-P10424 OPBP-1
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P99903 Simridarlimab
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro.

Species: Human

PD-1/PD-L1   CD47  
Cancer   Inflammation or Immune System Disease  
/
HY-125527S Resolvin D1-d5
Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α-mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages.
Isotope-Labeled Compounds   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-P10420 RS17
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.
CD47   Interleukin Related  
Cancer  
/
HY-P991490 ISB2001
ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD38   CD3   TNF Receptor  
Cancer  
/
HY-P6442 Chemerin15
Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.
Chemerin Receptor   Syk   ERK   Src   p38 MAPK   P-selectin  
Cerebrovascular Disease   Cardiovascular Disease   Ischemia-Reperfusion Injury  
/
HY-P99484 Botensilimab
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-101092A QS-21
QS-21 is a mixture of QS-21-Xyl (HY-101092B) and QS-21-Api (HY-101092), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria).
Toll-like Receptor (TLR)  
Cancer   Infection  
/
HY-159114 Whole Glucan Particles
Whole Glucan Particles is a Dectin-1a agonist. Whole Glucan Particles activates the innate immune system to improve the function of macrophages, monocytes and other immune cells.
C-type Lectin-like Receptors (CTLRs)   Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P990289 Anti-Mouse CD172a Antibody (P84)
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection.

Species: Mouse

Transmembrane Glycoprotein  
Salmonella Infection  
/
HY-NP0196 Mouse immunoglobulin G
Mouse Immunoglobulin G (Mouse IgG) is the most abundant glycoprotein in mouse serum, which bridges innate and adaptive immune responses. A conserved asparagine-297 residue on each heavy chain contains an N-linked glycosylation site. Mouse Immunoglobulin G shares many glycosylation features with human IgG, but contains N-Glycolylneuraminic acid (HY-128965) instead of N-acetylneuraminic acid (HY-I0400). Mouse Immunoglobulin G is widely used as a negative isotype control, immunoassay coating protein and research standard in the life sciences.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-N6714 Alternariol
Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.

Source: fungi of the genus Alternaria

Topoisomerase   Androgen Receptor   Estrogen Receptor/ERR   Apoptosis  
Infection  
/
HY-P0144 Thrombospondin-1 (1016-1023) (human, bovine, mouse)
Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide.
CD47   Apoptosis  
Digestive System Disease   Digestive System Inflammation  
/
HY-P99273 Vorsetuzumab
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma.

Species: Human

TNF Receptor  
Cancer  
/
HY-P3151 Gliadin p31-43
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research.
Others  
Inflammation or Immune System Disease  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-P99791 Orilanolimab
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P99759 Nogapendekin alfa (his tag)
Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8+ T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Non-Hodgkin Lymphoma  
/
HY-P2076 Dusquetide
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
p62   Bacterial  
Infection  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-P990858 Anti-CD47 Antibody (B6.H12)
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma.

Species: Human

CD47  
Cancer  
/
HY-159069 Zymosan (ZM), 95%
Zymosan (ZM), 95% is a yeast cell wall-derived carbohydrate-rich preparation and immunomodulator. Zymosan (ZM), 95% binds to and activates TLR-2, TLR-4, and Dectin-1 receptor to trigger downstream signaling pathways. Zymosan (ZM), 95% upregulates TLR-2, TLR-4, and TNF-α mRNA expression, increases serum TNF-α levels, and stimulates splenocyte number and viability in mice. Zymosan (ZM), 95% attenuates melanoma growth progression, modulates macrophage marker gene expression, and mediates phagocytosis, ROS generation, and cytokine production. Zymosan (ZM), 95% reduces Connexin 43 protein and mRNA levels, inhibits gap junctional intercellular communication, and induces proinflammatory factor production in human corneal cells. Zymosan (ZM), 95% induces peritoneal inflammation in mice, functions as a drug carrier, and supports fibroblast cell attachment in hydrogel formulations. Zymosan (ZM), 95% can be used for the research of melanoma, tumors, fungal keratitis, ocular surface inflammatory disorders, and peritoneal inflammation.
C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)   TNF Receptor   Connexin  
Cancer   Fungal Infection  
/
HY-P990033 Anzurstobart
Anzurstobart (CC-95251; BMS-986351) is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies.

Species: Human

CD47  
Colorectal Cancer   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P3333 KSPWFTTL
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P1587 IRBP (1-20), human
IRBP (1-20), human contains a major epitope for the H-2b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2b mice.
MHC  
Inflammation or Immune System Disease  
/
HY-P4193 AH1
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8+ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I Ld molecule. AH1 can be used for the research of colorectal carcinoma.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-124004 Acetyl-6-formylpterin
Acetyl-6-formylpterin (Ac-6-FP) is a hapten that stabilizes MR1 on antigen-presenting cells, forming an MR1:A6FP complex that fails to activate MAIT cell TCR, thereby acting as a competitive inhibitor of MAIT cell activation. Acetyl-6-formylpterin exacerbates house dust mite-induced airway hyperresponsiveness and elevates circulating IgE levels. Acetyl-6-formylpterin reduces systemic MAIT cell activity and decreases the frequency of IL-17A+ and IFNγ+ MAIT cells in the spleen. Acetyl-6-formylpterin is useful for the study of allergic asthma.
MHC   Interleukin Related   IFNAR  
Allergic Asthma  
/
HY-P99396 Spesolimab
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-W020780 mPEG5000-Mal
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses.
Biochemical Assay Reagents  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P10587 Icotrokinra
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
Interleukin Related   STAT   IFNAR  
Inflammation or Immune System Disease  
/
HY-P72111 Calreticulin/CALR Protein, Human (His)
The calreticulin/CALR protein is a calcium-binding molecular chaperone that promotes ER folding and quality control. It interacts with monoglucosylated glycoproteins and promotes nuclear export of NR3C1. Calreticulin/CALR Protein, Human (His) is the recombinant human-derived Calreticulin/CALR protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P74289 CD47 Protein, Mouse (HEK293, solution)
The CD47 protein, also known as integrin-associated protein (IAP), is an immune checkpoint protein. CD47 binds to membrane integrins and binds ligands platelet reaction-protein-1 (TSP-1) and signal regulatory protein alpha (SIRP伪). CD47 is a potential therapeutic target for some cancers and is also used to treat pulmonary fibrosis. CD47 Protein, Mouse (HEK293, solution) is the recombinant mouse-derived CD47 protein, expressed by HEK293 , with tag free.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P78561 CD47 Protein, Human (Biotinylated, HEK293, mFc-Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (Biotinylated, HEK293, mFc-Avi) is the recombinant human-derived CD47 protein, expressed by HEK293 , with C-mFc, C-Avi labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P78908 CD47 Protein, Human (Biotinylated, HEK293, hFc-Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (Biotinylated, HEK293, hFc-Avi) is the recombinant human-derived CD47 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P78710 CD47 Protein, Mouse (HEK293, mFc)
The CD47 protein is an adhesive multifunctional protein that coordinates cell-cell interactions, serves as a THBS1 receptor, and regulates integrin signaling through heterotrimeric G proteins. It plays a key role in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cell self-renewal, immune regulation, and memory formation. CD47 Protein, Mouse (HEK293, mFc) is the recombinant mouse-derived CD47 protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P78639 CD47 Protein, Canine (HEK293, His)
The CD47 protein is an adhesive multifunctional protein that coordinates cell-cell interactions, serves as a THBS1 receptor, and regulates integrin signaling through heterotrimeric G proteins. It plays a key role in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cell self-renewal, immune regulation, and memory formation. CD47 Protein, Canine (HEK293, His) is the recombinant canine-derived CD47 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD47 Protein, Canine (HEK293, His) is 122 a.a., with molecular weight of 27-32 kDa.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P7712 Calreticulin-3/CALR3 Protein, Human
Calreticulin-3/CALR3 Protein, Human is a recombinant human Calreticulin-3 expressed in E. coli. Calreticulin (CRT) is a highly conserved chaperone-like lectin that regulates Ca2+ homeostasis and participates in protein quality control in the endoplasmic reticulum (ER).

Species: Human; Source: E. coli

/
HY-P78611 CD47 Protein, Rabbit (HEK293, Fc)
The CD47 protein is an adhesive multifunctional protein that coordinates cell-cell interactions, serves as a THBS1 receptor, and regulates integrin signaling through heterotrimeric G proteins. It plays a key role in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cell self-renewal, immune regulation, and memory formation. CD47 Protein, Rabbit (HEK293, Fc) is the recombinant Rabbit-derived CD47 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD47 Protein, Rabbit (HEK293, Fc) is 121 a.a., with molecular weight of 48-58 kDa.

Species: Rabbit; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P71722 Calreticulin/CALR Protein, Pig (P.pastoris, His)
Calreticulin (CALR) is an essential calcium-binding chaperone involved in ER functions. It interacts with glycoproteins, facilitates NR3C1 nuclear export, regulates maternal gene expression, and aids in oocyte maturation. CALR is released during oocyte activation and prevents polyspermy. It forms an EIF2 complex with CELF1/CUGBP1, CALR3, EIF2S1, EIF2S2, HSP90B1, and HSPA5 and interacts with PDIA3/ERp57, SPACA9, TRIM21, PPIB, PDIA5, and CLCC1. Calreticulin/CALR Protein, Pig (P.pastoris, His) is the recombinant pig-derived Calreticulin/CALR protein, expressed by P. pastoris , with N-His labeled tag.

Species: Pig; Source: P. pastoris

/
HY-P706004 Calreticulin/CALR Protein, Mouse (P.pastoris, C-His)
The calreticulin/CALR protein acts as a calcium-binding partner and promotes endoplasmic reticulum folding, assembly, and quality control. It interacts with monoglucosylated glycoproteins and mediates nuclear export of the NR3C1 DNA-binding domain. Calreticulin/CALR Protein, Mouse (P.pastoris, C-His) is the recombinant mouse-derived Calreticulin/CALR protein, expressed by P. pastoris , with C-6*His labeled tag.

Species: Mouse; Source: P. pastoris

/
HY-P704477 CD47 Protein, Human (HEK293, mFc)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (HEK293, mFc) is the recombinant human-derived CD47 protein, expressed by HEK293, with C-mFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P704478 CD47 Protein, Human (HEK293, His, Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (HEK293, His, Avi) is the recombinant human-derived CD47 protein, expressed by HEK293, with C-Avi and C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P705096 SIRP alpha V8/CD172a Protein, Human (Biotinylated, HEK293, His-Avi)

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P705250 CD47 Protein, Mouse (Biotinylated, HEK293, Fc-Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Mouse (Biotinylated, HEK293, Fc-Avi) is the recombinant mouse-derived CD47 protein, expressed by HEK293 , with C-Avi, C-Fc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P84512 CD47 Antibody (YA4209)
CD47 Antibody (YA4209) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD47.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86567 Calreticulin Antibody (YA6259)
Calreticulin Antibody (YA6259) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Calreticulin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80065 CD47 Antibody (YA531)
CD47 Antibody (YA531) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD47.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P88032 CD47 Antibody (YA7717)
CD47 Antibody (YA7717) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD47.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84229A Calreticulin Antibody (YA3926)(PBS only)
Calreticulin Antibody (YA3926) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Calreticulin.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P84512A CD47 Antibody (YA4209)(PBS only)
CD47 Antibody (YA4209) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD47.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85073 Calreticulin Antibody (YA4765)
Calreticulin Antibody (YA4765) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Calreticulin.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/

Keywords

phagocytosis checkpoint | tumor immune escape | CD47 | SIRPα | macrophage phagocytosis | calreticulin | innate immunity | cancer immunotherapy | CAR-macrophage